Last update :
03/05/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Local anesthetic   Ropivacain hydrochloride  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Narop Sweden
Naropéine France, Greece, Portugal
Naropin Argentina, Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Great Britain, Hungary, Iceland, Ireland, Luxembourg, Malaysia, Mexico, New Zealand, Norway, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United States of America
Naropina Italy
Ropiconest Mexico
Ropivacain Belgium, Germany, Norway, Romania
Ropivacain hydrochlorid Canada, Germany
Ropivacaina Chile, Spain
Ropivacaine Belgium, Canada, United States of America
Rovacin Sweden
Stability of mixtures   Injection   Stability of mixtures : Ropivacain hydrochloride     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 1,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Fentanyl citrate 3 µg/ml
2-8°C
51 Day
Protect from light 1832
Level of evidence B
Glass Sodium chloride 0,9% 1,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Fentanyl citrate 3 µg/ml
20°C
51 Day
With or without light 1832
Level of evidence B
Polyvinyl chloride Sodium chloride 0,9% 1,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Fentanyl citrate 3 µg/ml
2-8°C
11 Day
Protect from light 1832
Level of evidence B
Polyvinyl chloride Sodium chloride 0,9% 1,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Fentanyl citrate 3 µg/ml
20°C
11 Day
With or without light 1832
Level of evidence B
Polyvinyl chloride Sodium chloride 0,9% 1,2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Sufentanil citrate 0,00075 mg/ml
4°C
180 Day
Not specified 4522
Level of evidence B
Polypropylene Sodium chloride 0,9% 1 & 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Morphine sulfate 0,02 mg/ml
30°C
30 Day
Protect from light 1665
Polypropylene Sodium chloride 0,9% 1 & 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Sufentanil citrate 0,0004 mg/ml
30°C
30 Day
Protect from light 1665
Polypropylene Sodium chloride 0,9% 1 & 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Fentanyl citrate 1 µg/ml
30°C
30 Day
Protect from light 1665
Polypropylene Sodium chloride 0,9% 1 & 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Clonidine hydrochloride 0.05 & 0.005 mg/ml
30°C
30 Day
Protect from light 1665
Polypropylene Sodium chloride 0,9% 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Morphine sulfate 0,1 mg/ml
30°C
30 Day
Protect from light 1665
Polypropylene Sodium chloride 0,9% 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Sufentanil citrate 0,004 mg/ml
30°C
30 Day
Protect from light 1665
Polypropylene Sodium chloride 0,9% 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Fentanyl citrate 10 µg/ml
30°C
30 Day
Protect from light 1665
Polypropylene Sodium chloride 0,9% 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Clonidine hydrochloride 0.005 mg/ml
30°C
30 Day
Protect from light 1665
Polypropylene None 1 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Diamorphine hydrochloride 0,045 mg/ml
21°C
16 Day
Not specified 2051
Level of evidence D
Polypropylene None 1,2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Methylprednisolone acetate 16 mg/ml
23°C-25°C
30 Day
With or without light 1620
Polypropylene None 1 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Diamorphine hydrochloride 0,045 mg/ml
40°C
6 Day
Not specified 2051
Level of evidence D
Polypropylene None 1,2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Methylprednisolone acetate 16 mg/ml
4°C
30 Day
Protect from light 1620
Polypropylene None 1 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Diamorphine hydrochloride 0,045 mg/ml
4°C
30 Day
Not specified 2051
Level of evidence D
Polyolefine Sodium chloride 0,9% 6 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Morphine sulfate 2 mg/ml
Injection   Ziconotide acetate 0,2 µg/ml
18-24°C
14 Day
Not specified 3998
Level of evidence D
Polyolefine Sodium chloride 0,9% 1 & 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Butorphanol tartrate 0.05 mg/ml
25°C
15 Day
Protect from light 3780
Level of evidence A
Polyolefine Sodium chloride 0,9% 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Tramadol hydrochloride 4 mg/ml
25°C
15 Day
With or without light 3296
Level of evidence C
Polyolefine Sodium chloride 0,9% 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Tramadol hydrochloride 4 mg/ml
4°C
15 Day
Protect from light 3296
Level of evidence C
Polyolefine Sodium chloride 0,9% 1 & 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Butorphanol tartrate 0.05 mg/ml
4°C
15 Day
Protect from light 3780
Level of evidence A
Ethylene vinyl acetate Sodium chloride 0,9% 1,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Fentanyl citrate 3 µg/ml
2-8°C
51 Day
Protect from light 1832
Level of evidence B
Ethylene vinyl acetate Sodium chloride 0,9% 1,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Fentanyl citrate 3 µg/ml
20°C
51 Day
With or without light 1832
Level of evidence B
Polypropylen Syringe Sodium chloride 0,9% 7.5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Morphine sulfate 3,5 mg/ml
Injection   Ziconotide acetate 1 µg/ml
2-8°C
3 Day
Not specified 3998
Level of evidence D
Polypropylen Syringe Sodium chloride 0,9% 1,2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Sufentanil citrate 0,00075 mg/ml
4°C
180 Day
Not specified 4522
Level of evidence B
Synchromed® Sodium chloride 0,9% 0,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Morphine sulfate 0,5 mg/ml
Injection   Ziconotide acetate 0,5 µg/ml
37°C
14 Day
Protect from light 4669
Level of evidence B+
Synchromed® Sodium chloride 0,9% 8,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Morphine sulfate 6 mg/ml
Injection   Ziconotide acetate 0,5 µg/ml
37°C
21 Day
Protect from light 4669
Level of evidence B+
Synchromed® Sodium chloride 0,9% 8,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Morphine sulfate 0,5 mg/ml
Injection   Ziconotide acetate 0,5 µg/ml
37°C
60 Day
Protect from light 4669
Level of evidence B+
Synchromed® Sodium chloride 0,9% 0,5 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Morphine sulfate 0,5 mg/ml
Injection   Ziconotide acetate 2 µg/ml
37°C
60 Day
Protect from light 4669
Level of evidence B+
Not specified None 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Diamorphine hydrochloride 0,025 mg/ml
21°C
28 Day
Not specified 2051
Level of evidence D
Not specified None 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Diamorphine hydrochloride 0,025 mg/ml
40°C
6 Day
Not specified 2051
Level of evidence D
Not specified None 2 mg/ml
Injection   Ropivacain hydrochloride   
Injection   Diamorphine hydrochloride 0,025 mg/ml
4°C
70 Day
Not specified 2051
Level of evidence D
  Mentions Légales